A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors

Various clinical trials have evaluated first- to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as the first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). Although recent research evidence supports the use of third-generation TKIs such as osimertinib as therapeutic agents for patients with EGFR-mutated NSCLC, there are no reports of clinical trials comparing second-generation such as afatinib and third-generation TKIs. Further prospective evaluation is required.